

Ibiglustat (L-Malic acid)

Chemical Properties


CAS No. : 1629063-78-0

Formula: C₂₄H₃₀FN₃O₇S

Molecular Weight: 523.57

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's.
Targets(IC50)	Transferase
In vitro	Ibiglustat (L-Malic acid) (1 μM) treated Fabry disease cells are close to the physiological level in untreated WT cells in GL-3 levels. Ibiglustat (L-Malic acid) prevents additional GL-3 accumulation and ameliorates the abundant GL-3 levels in FD cardiomyocytes[4].

Solubility Information

Solubility	DMSO: 90 mg/mL (171.9 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.3 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.910 mL	9.5498 mL	19.0996 mL
5 mM	0.382 mL	1.910 mL	3.8199 mL
10 mM	0.191 mL	0.955 mL	1.910 mL
50 mM	0.0382 mL	0.191 mL	0.382 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Glucosylceramide Synthase Inhibitors. WO 2015089067 A1.

Iva Stojkowska, et al. Molecular mechanisms of α -synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2017.

Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9 (14), 1687-1700.

Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481